growth hormone comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-12-27. Numbers and descriptions here follow the published literature rather than marketing material.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Wide nose – To narrow a too-wide nose, the plastic surgeon cuts, contours, and rearranges the craniofacial bones to achieve the desired functional and aesthetic outcome of a narrower, straighter nose. To leave no visible, surgical scars upon the new nose, the surgeon effects the osteotome (bone chisel) incisions to the nasal bones beneath the facial skin. Illustration 1: The surgeon cuts the excessively wide bones of the upper nasal dorsum (violet) with an osteotome (bone chisel), then detaches, corrects, and relocates them inwards, to a position, between the ocular orbits (red), that narrows the width of the nasal dorsum. Illustration 2: The surgeon chisels two cuts (incisions) to the nasal bones, each incision begins at the nasal cavity. The first incision begins at the yellow dot and extends upwards, along the green arrow, until meeting the zig-zag line (red). The second incision begins at the blue dot and extends upwards, along the black arrow, until meeting the zig-zag line (red). Once cut and loosened from the face, the nasal bone pieces are corrected, then pushed inwards and re-set, thus narrowing the nose.
Under reducing conditions, the blue-colored methylene blue cation (MB+) gains 1H+ and 2e− to become the electrically neutral and colorless leucomethylene blue (LMB). The redox midpoint potential E0' is +0.01 V. The redox properties can be seen in a classical demonstration of chemical kinetics in general chemistry, the "blue bottle" experiment. Typically, a solution is made of glucose (dextrose), methylene blue, and sodium hydroxide. Upon shaking the bottle, oxygen oxidizes methylene blue, and the solution turns blue. The dextrose will gradually reduce the methylene blue to its colorless, reduced form. Hence, when the dissolved dextrose is entirely consumed, the solution will turn blue again. In the mitochondrial electron transport chain, reduced methylene blue (MBH2) directly reduces cytochrome c rather than to oxygen, limiting the formation of superoxide. Methylene blue has been shown to directly accept electrons from NADH, NADPH, and FADH2.
ELPs modified with certain functional groups have the capacity to be conjugated with drugs, including chemotherapeutic agents. Together, the ELP-drug complex can be taken up by tumor cells to a greater extent, promoting the cytotoxic activity of the drug. The reason that the complexes preferentially target the tumor cells is that these cells tend to be associated with more permeable blood vessels and also possess a weaker lymphatic presence. This essentially means that the drugs can cross over from the vessels to the tumor cells more frequently and can remain in the vessels for a longer period of time, without being filtered out. The phase transition associated with ELPs can also be used to promote tumor cell uptake of the drug. By locally heating tumor cell regions, the ELP-drug complex will aggregate into spherical clumps. If this ELP-drug complex is engineered to expose functional domains in the spherical clump shape that are recognized by tumor cell surfaces, then this cell surface interaction would promote uptake of the drug as the tumor cell would mistake the ELP-drug complex as being a harmless substance.
Sources: en.wikipedia.org
== Side effects == Side effects of LGD-4033 may include headache and dry mouth. LGD-4033 has been found to dose-dependently decrease levels of total testosterone, free testosterone, follicle-stimulating hormone (FSH), sex hormone-binding globulin (SHBG), HDL cholesterol, and triglycerides, while not affecting levels of luteinizing hormone (LH), total cholesterol, LDL cholesterol, or prostate-specific antigen (PSA). Due to the decreased ratio of HDL cholesterol to LDL cholesterol, LGD-4033 could theoretically increase the risk of heart attack and stroke. Elevated liver enzymes, such as increased levels of aspartate aminotransferase (AST) or alanine aminotransferase (ALT), have not been reported with LGD-4033 in the few conducted clinical trials thus far. However, multiple case reports of hepatotoxicity with LGD-4033 in the setting of non-medical use have been published. LGD-4033 and other SARMs are largely uncharacterized in terms of their potential for masculinizing effects, for example in women. In addition, the effects and safety of high doses of LGD-4033 and other SARMs, which are often used in non-medical contexts, are unknown. Anecdotal reports of masculinization with black-market SARMs in women exist in online forums. The United States Food and Drug Administration (FDA) claims that "liver toxicity, adverse effects on blood lipid levels, and a potential to increase the risk of heart attack and stroke" are among the potential adverse health effects of SARMs including LGD-4033.
The confirmation test in most laboratories (and all SAMHSA certified labs) is performed using mass spectrometry, and is precise but expensive. False positive samples from the screening test will almost always be negative on the confirmation test. Samples testing positive during both screening and confirmation tests are reported as positive to the entity that ordered the test. Most laboratories save positive samples for some period of months or years in the event of a disputed result or lawsuit. For workplace drug testing, a positive result is generally not confirmed without a review by a Medical Review Officer who will normally interview the subject of the drug test.
== History == After its initial US FDA approval, due to the pro-arrhythmic potential, it was only made available to hospitals and prescribers that had received education and undergone specific training in the risks of treatment with dofetilide; however, this restriction was subsequently removed in 2016.
Sources: en.wikipedia.org
== Hazards == As a radioactive material, 226Ra and its decay products can present serious health hazards. Factory workers who worked with radium-containing luminous paint, known as the Radium Girls, often licked the tips of their paintbrushes in order to produce a finer point. In doing so, the workers ingested some of the radioactive paint; this eventually led to serious health problems including cancer, bone damage, and anemia. Several of these workers died from illnesses caused by radium exposure. Many rocks and soils contain low concentrations of 226Ra, which forms from the radioactive decay of naturally occurring uranium. The decay of 226Ra produces radon-222, a radioactive gas that can accumulate in inadequately ventilated homes and other enclosed spaces. Radon exposure is the second leading cause of lung cancer in the United States.
== Production and occurrence == Pentane is produced by fractional distillation of petroleum and purified by rectification (successive distillations). It occurs in alcoholic beverages and in hop oil. It is a component of exhaled breath for some individuals. A degradation product of unsaturated fatty acids, its presence is associated with some diseases and cancers. Pentane is a relatively minor component of automobile gasoline, with its share varying within 1–6% in 1990s Sweden, 2–13% in 1990s US and 1–3% in the US in 2011. At 62, its octane number (both RON and MON) is quite low.
In 2023, Vasquez introduced bipartisan legislation aimed at addressing the teacher shortage in Indian Country. The bill proposed providing federal pension benefits to educators working in tribal schools, seeking to improve teacher retention and support Native American students. Vasquez voted that year in favor of requiring healthcare workers to receive the COVID-19 vaccine. The following day, he opposed a resolution to end the COVID-19 national emergency. On women's health, he has supported abortion rights and advocated for codifying Roe v. Wade into federal law. In 2024, Vasquez voted in favor of the Protecting Americans from Foreign Adversary Controlled Applications Act, sometimes called the TikTok ban, which sought to address concerns over data security and foreign influence. On July 19, he called for President Joe Biden to withdraw from the 2024 presidential election, citing concerns over his age and ability to campaign effectively. In December 2025, NBC News and The New York Times reported that Vasquez had voted against a bill to reopen the federal government and then touted the money the bill delivered to his district. After the federal government was reopened, primarily with Republican votes, after a 43-day shutdown, Vasquez was among Democrats who "claimed credit for some provisions in the bill." Former Speaker Nancy Pelosi coined the term "vote no and take the dough" when Republicans took credit for money brought to their districts under bills they opposed.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.